Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celgene Names Julia A. Haller To Board

This article was originally published in Scrip

Executive Summary

Celgene Corp. has appointed Julia A. Haller to its board of directors. Haller is ophthalmologist-in-chief of the Wills Eye Hospital and holds the William Tasman, M.D. endowed chair. She is also professor and chair of the department of ophthalmology at Jefferson Medical College of Thomas Jefferson University and Thomas Jefferson University Hospitals and is co-director of the Wills Vision Research Center at Jefferson. Previously Haller was the first female chief resident at the Wilmer Eye Institute at Johns Hopkins and later joined its faculty. She was named the inaugural Katharine Graham professor ophthalmology in 2002 and the inaugural Robert Bond Welch, M.D. professor of ophthalmology in 2006.

You may also be interested in...



Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?

How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.

Adherence Issues Add Weight To Digital Trials Push

Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.

Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus

This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC030073

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel